Literature DB >> 3338034

Changing expression of ABH blood group and cryptic T-antigens of noninvasive and superficially invasive papillary transitional cell carcinoma of the bladder from initial occurrence to malignant progression.

T Yamada1, I Fukui, M Yokokawa, H Oshima.   

Abstract

Thirteen patients who developed malignant progression after frequent recurrence of noninvasive or superficially invasive (Ta or T1) papillary transitional cell carcinoma of the bladder were studied for expression of ABH-antigens in tumor tissues throughout their clinical courses and cryptic Thomsen-Friedenreich antigen (T-Ag) expression in the tumor tissues was examined simultaneously in nine of them. Five patients who experienced recurrent bladder tumors for more than 5 years without any malignant progression were served as control. ABH-antigens in initial tumors were negative in only two of 13 patients developing malignant progression and in two of five controls. Cryptic T-Ag was positive in all patients examined. Recurrent tumors revealed eliminated or decreased expression of ABH-antigens and cryptic T-Ag before malignant progression in, respectively, ten of 11 and six of nine patients with antigen-positive initial tumors. In contrast, recurrent tumor of controls with antigen-positive initial tumors showed neither elimination nor decrease in expression of antigens throughout their clinical courses.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3338034     DOI: 10.1002/1097-0142(19880215)61:4<721::aid-cncr2820610415>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Analysis of tissue ABH antigens in superficial bladder tumours.

Authors:  H Tsujihashi; H Matsuda; S Uejima; T Akiyama; T Kurita
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

2.  The human repertoire of antibody specificities against Thomsen-Friedenreich and Tn-carcinoma-associated antigens as defined by human monoclonal antibodies.

Authors:  B Jansson; C A Borrebaeck
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Prognostic value of an assessment of ABH(0) isoantigens and Thomsen-Friedenreich (TF) antigen expression in patients with urinary bladder tumours.

Authors:  Z F Dobrowolski; D Duś; J Hałasa; C Radzikowski
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

4.  Targeted O-glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advanced-stage bladder tumours.

Authors:  Sofia Cotton; Rita Azevedo; Cristiana Gaiteiro; Dylan Ferreira; Luís Lima; Andreia Peixoto; Elisabete Fernandes; Manuel Neves; Diogo Neves; Teresina Amaro; Ricardo Cruz; Ana Tavares; Maria Rangel; André M N Silva; Lúcio Lara Santos; José Alexandre Ferreira
Journal:  Mol Oncol       Date:  2017-03-02       Impact factor: 6.603

5.  ST3Gal.I sialyltransferase relevance in bladder cancer tissues and cell lines.

Authors:  Paula A Videira; Manuela Correia; Nadia Malagolini; Hélio J Crespo; Dário Ligeiro; Fernando M Calais; Helder Trindade; Fabio Dall'Olio
Journal:  BMC Cancer       Date:  2009-10-07       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.